Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review noted that alopecia areata is an autoimmune disease impacting hair follicles and offered insights into its complex pathogenesis involving immune responses, while highlighting ongoing research into new treatments such as Janus kinase inhibitors and other immunomodulatory drugs.

This article reviews treatment options for male-pattern and female-pattern hair loss, telogen effluvium, and alopecia areata, but provides no new clinical results; algorithmic management approaches are included.

This study suggests that mesenchymal stem cell therapy may improve cell viability and regulate key signaling pathways in vitro for treating alopecia areata.

This review discusses oxidative stress in alopecia areata pathogenesis and potential treatment strategies, reporting no new clinical results but suggesting biomarkers for oxidative stress and discussing JAK inhibitors as promising options.

This review covers nonsteroid-based therapies for alopecia areata, finding potential in PRP, UVR, and laser treatments, but highlights a lack of high-quality evidence for their efficacy.

This study found that baricitinib improved symptoms of atopic dermatitis and alopecia areata in both adults and children in real-world settings, aligning with clinical trial results, while noting low discontinuation due to adverse events and no new safety concerns.

In this study, fractional CO2 laser treatment for alopecia areata was found to significantly increase terminal hair and patient satisfaction compared to betamethasone valerate cream alone, highlighting its efficacy and safety both as a standalone and combined treatment.

This report describes a rare case of alopecia areata coexisting with primary scarring alopecia, diagnosed through detailed trichoscopic investigation, highlighting the importance of comprehensive examination for accurate diagnosis.

Results are not reported in this abstract, which notes that while Janus kinase inhibitors like baricitinib show therapeutic benefits for alopecia areata, the mechanisms and reliable predictors of response remain unclear.

This study found that DPCP immunotherapy effectively treats alopecia areata, identifying factors that influence treatment response and patient satisfaction, which may aid in standardizing the treatment for improved outcomes.

This review suggests that oral Janus kinase inhibitors like tofacitinib, ruxolitinib, and baricitinib show promise for treating alopecia areata in adults, both in terms of efficacy and safety.

This literature review highlights challenges in managing alopecia areata in the Middle East and Africa, noting significant regional gaps in data, treatment guidelines, and public awareness that impede patient care and emphasize the need for improved support and resources.

This review highlights that laser and light treatments could serve as safe and effective alternatives to current therapies for alopecia areata, with the excimer laser showing positive results, though further randomized controlled trials are necessary to establish optimal treatment protocols.

This review discusses the role of immune cells in the pathogenesis of alopecia areata and highlights emerging immunomodulatory strategies and novel therapeutic targets aimed at offering more effective and durable treatments for this autoimmune hair loss disorder.

This article reviews current and emerging treatments for alopecia areata, including Janus kinase inhibitors, highlighting variability in clinical outcomes and the lack of sustained remission.

This article reviews treatment options and psychological impacts of alopecia areata and reports no new clinical findings.

This study found that pediatric patients with severe alopecia areata showed significant improvement with systemic corticosteroids but typically experienced relapse within 4-5 months, also seeing an increase in weight percentiles.

This review discusses various treatment options for Alopecia Areata, focusing on both medical and psychological approaches, and reports no new clinical results.

In this review, researchers examined the concentration of cortisol in scalp hair of individuals with alopecia areata to explore its relationship with disease variables, as cortisol in hair can indicate chronic stress, which may impact alopecia areata pathogenesis.

This review discusses the effects of photobiomodulation, particularly its potential to reduce inflammation in various conditions, but it does not report new clinical findings.

This review discusses the modern approach of skin tissue engineering for chronic wound treatment, focusing on bioengineered artificial skin substitutes and assessing innovations in biomaterials and cell use; it reports no new clinical results.

This study found that patients with alopecia areata experience significant impairments in health-related quality of life, notably affecting mental health, according to various quality of life assessment tools.

This consensus statement outlines a treatment algorithm for alopecia areata, discussing when to consider systemic treatment and how to assess outcomes, without providing new clinical results.

This review discusses recent advances and ongoing clinical trials in novel therapeutics for alopecia areata, despite the lack of current FDA-approved treatments for severe cases, and reports no new results.

This article reviews the reported sexual and psychological side effects of 5-alpha reductase inhibitors for benign prostatic hyperplasia, emphasizing the need for further clinical studies.

This review highlights the challenges in treating alopecia areata, noting that current therapies often lead to relapse and have uncertain long-term effectiveness; it also points to potential future treatments such as JAK-STAT inhibitors and PRP.

This study discusses a hypothesis for repurposing non-cancer drugs and combining micronutrients to target cancer and cancer stem cells with fewer side effects, suggesting a potential new approach for more effective cancer therapy.

This study found that tofacitinib shows reasonable effectiveness for treating alopecia areata with mild adverse effects, although more large-scale randomized trials are needed to fully assess its safety and efficacy.

This review discusses updated treatment guidelines for alopecia areata in Japan, highlighting new options like corticosteroid pulse therapy, but reports no new clinical results.

This article discusses the etiology, clinical features, diagnosis, histopathology, and treatment of alopecia areata but reports no new clinical findings; it emphasizes the palliative nature of current treatments.